PLK1 and melanoma: Taken together, these analyses show that mitochondrial signatures are associated with distinct responses to RSK and PLK1 inhibitors (Fig 7J) and that targeting specific mitochondrial proteins is a valid approach to fine-tune the sensitivity of melanoma cells to PLK1 inhibition.